Rani Therapeutics Holdings, Inc. (RANI)

NASDAQ: RANI · IEX Real-Time Price · USD
8.11
+0.09 (1.12%)
Nov 29, 2022 4:00 PM EDT - Market closed
1.12%
Market Cap 407.00M
Revenue (ttm) 2.72M
Net Income (ttm) -76.61M
Shares Out 24.47M
EPS (ttm) -1.11
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 10,116
Open 8.22
Previous Close 8.02
Day's Range 8 - 8.28
52-Week Range 5.62 - 31.38
Beta n/a
Analysts Buy
Price Target 24.23 (+198.8%)
Earnings Date Nov 21, 2022

About RANI

Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics. The company develops the RaniPill capsule, a platform that is intended to replace subcutaneous or IV injection of biologics with oral dosing. Its product pipeline includes RT-101, an octreotide, which has completed Phase I clinical trial for the treatment of neuroendocrine tumors and acromegaly; RT-105, an anti-TNF-alpha antibody to treat psoriatic arthritis; RT-102, a parathyroid hormone that is in preclinical stud... [Read more]

Industry Biotechnology
IPO Date Jul 30, 2021
CEO Talat Imran
Employees 114
Stock Exchange NASDAQ
Ticker Symbol RANI
Full Company Profile

Financial Performance

In 2021, RANI's revenue was $2.72 million, an increase of 488.10% compared to the previous year's $462,000. Losses were -$53.09 million, 217.8% more than in 2020.

Financial Statements

Analyst Forecast

According to 14 analysts, the average rating for RANI stock is "Buy." The 12-month stock price forecast is 24.23, which is an increase of 198.77% from the latest price.

Price Target
$24.23
(198.77% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Rani Therapeutics Holdings, Inc. (RANI) Reports Q3 Loss, Lags Revenue Estimates

Rani Therapeutics Holdings, Inc. (RANI) delivered earnings and revenue surprises of 0% and 100%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the ...

2 weeks ago - Zacks Investment Research

Rani Therapeutics to Present at the Stifel Healthcare Conference

SAN JOSE, Calif., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical stage biotherapeutics company focused on the oral delivery...

2 weeks ago - GlobeNewsWire

Here's Why Rani Therapeutics Holdings, Inc. (RANI) Is a Great 'Buy the Bottom' Stock Now

Rani Therapeutics Holdings, Inc. (RANI) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate rev...

1 month ago - Zacks Investment Research

Rani Therapeutics Announces New RT-111 Development Program and Provides Corporate Update

- Rani announces preclinical development of RT-111, a RaniPill GO capsule containing ustekinumab biosimilar for the potential treatment of psoriatic arthritis, ulcerative colitis, Crohn's disease and ps...

1 month ago - GlobeNewsWire

Rani Therapeutics to Present at the H.C. Wainwright 24th Annual Global Investment Conference

SAN JOSE, Calif., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical stage biotherapeutics company focused on the oral deliver...

2 months ago - GlobeNewsWire

Rani Therapeutics Announces Termination of Public Offering of Class A Common Stock

SAN JOSE, Calif., Aug. 11, 2022 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or the “Company”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral d...

3 months ago - GlobeNewsWire

Rani Therapeutics Holdings, Inc. (RANI) Reports Q2 Loss, Misses Revenue Estimates

Rani Therapeutics Holdings, Inc. (RANI) delivered earnings and revenue surprises of -10.71% and 100%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the ...

3 months ago - Zacks Investment Research

Rani Therapeutics Announces Proposed Public Offering of Class A Common Stock

SAN JOSE, Calif., Aug. 10, 2022 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biolog...

3 months ago - GlobeNewsWire

Rani Therapeutics Reports Second Quarter 2022 Financial Results; Provides Corporate Update

- Announced positive topline Phase 1 results of RT-102 for the treatment of osteoporosis -

3 months ago - GlobeNewsWire

Rani Therapeutics Announces Positive Topline Results from Phase 1 Study of RT-102 in Osteoporosis

- RT-102 was generally well-tolerated, with no RaniPill™-related adverse events -

3 months ago - GlobeNewsWire

Rani Therapeutics Enters into $45 Million Loan Agreement to Support Ongoing RaniPill® Platform Advancement and Clinic...

Extends Rani's projected cash runway into mid-2024 Extends Rani's projected cash runway into mid-2024

3 months ago - GlobeNewsWire

Rani Therapeutics Reports First Quarter 2022 Financial Results; Provides Corporate Update

- Initiated a Phase 1 clinical trial of RT-102 for the treatment of osteoporosis –

6 months ago - GlobeNewsWire

Rani Therapeutics to Present at Upcoming Investor Conferences

SAN JOSE, Calif., May 03, 2022 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical stage biotherapeutics company focused on the oral delivery ...

6 months ago - GlobeNewsWire

Rani Therapeutics to Present at the 21st Annual Needham Virtual Healthcare Conference

SAN JOSE, Calif., April 07, 2022 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical stage biotherapeutics company focused on the oral deliver...

7 months ago - GlobeNewsWire

Rani Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results; Provides Corporate Update

- Initiated a Phase 1 clinical trial of RT-102 for the potential treatment of osteoporosis -

8 months ago - GlobeNewsWire

Rani Therapeutics to Release Fourth Quarter and Full Year 2021 Financial Results on Tuesday, March 29, 2022

SAN JOSE, Calif., March 23, 2022 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical stage biotherapeutics company focused on the oral deliver...

8 months ago - GlobeNewsWire

Rani Therapeutics Announces Initiation of Phase 1 Study of RT-102 Oral PTH for Osteoporosis

SAN JOSE, Calif., March 23, 2022 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical stage biotherapeutics company focused on the oral deliver...

8 months ago - GlobeNewsWire

Rani Therapeutics Reports Third Quarter 2021 Financial Results, Provides Corporate Update

SAN JOSE, Calif., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical stage biotherapeutics company focused on the oral delivery...

1 year ago - GlobeNewsWire

Rani Therapeutics Appoints Lyn Baranowski to Board of Directors

SAN JOSE, Calif., Nov. 12, 2021 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical stage biotherapeutics company focused on advancing technol...

1 year ago - GlobeNewsWire

This Recent Biologics IPO Could Be Heading Toward a Gain of 60% or More

A game-changing pill from Rani Therapeutics may offer an easier alternative to fight debilitating diseases.

1 year ago - The Motley Fool

Rani Therapeutics to Present at Cantor Fitzgerald Virtual Global Healthcare Conference

SAN JOSE, Calif., Sept. 23, 2021 (GLOBE NEWSWIRE) -- Rani Therapeutics (Nasdaq: RANI), a clinical stage biotherapeutics company focused on the oral delivery of biologics, today announced that the compan...

1 year ago - GlobeNewsWire

Rani Therapeutics Reports Second Quarter 2021 Financial Results, Provides Corporate Update

- IPO in July 2021 raised $84.3 million in gross proceeds - - Talat Imran Appointed Chief Executive Officer - - Enhanced leadership team with key management and board of directors' appointments -

1 year ago - GlobeNewsWire

Rani Therapeutics, RxSight: 2 Bullish Health Care Stock Picks From BofA

Rani Therapeutics Holdings, Inc. (NASDAQ:RANI), an early stage platform technology company that promotes oral dosing with its RaniPill, and RxSight, Inc. (NASDAQ:RXST), an ophthalmology-focused MedTech ...

Other symbols: RXST
1 year ago - Benzinga

Rani Therapeutics Announces Closing of its Initial Public Offering and Full Exercise of Underwriters' Option to Purch...

SAN JOSE, Calif., Aug. 13, 2021 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (Nasdaq:RANI) (“Rani Therapeutics” or “Rani”), a clinical stage biotherapeutics company focused on advancing technolo...

1 year ago - GlobeNewsWire

Rani Therapeutics' $73M IPO will fund upcoming clinical trials

Rani Therapeutics, a San Jose-based company developing a pill to replace medical injections, went public on Friday.  According to S-1 filings, shares were estimated to price between $14 and $16 last week.

1 year ago - TechCrunch